S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting|
|Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting|
|Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma|
|Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting|
|Hecla to Present at Cowen and Company Conference (2014/11/7)|
|Hecla Third Quarter 2014 Financial Results Conference Call and Webcast (2014/10/27)|
|Hecla Reports Third Quarter 2014 Results (2014/11/5)|
|Hecla to Participate at Scotiabank and Bank of America Merrill Lynch Conferences (2014/11/20)|
|Hecla Declares Preferred Dividend (2014/12/1)|
|Hecla Reports Preliminary 2014 Production Results of 11.1 Million Ounces of Silver and 186,994 Ounces of Gold (2015/1/14)|
Click above to view more mutual fund data and stats for hl - Hecla Mining Co GDR.